India Pharma Outlook Team | Friday, 10 October 2025
Jubilant Pharmova declared that its wholly owned subsidiary, Jubilant HollisterStier LLC (JHS), a major contract manufacturer specializing in sterile injectables in the North American pharmaceutical industry, has effectively started its new Sterile Fill & Finish line—its third—at the Spokane facility in Washington, US.
The initiation was symbolized by the first batch production, thus the beginning of income from the new line and the facility's capacity growing by 50%, a gesture that signifies the achievement of a key milestone in JHS' multi-stage expansion plan.
The advanced isolator technology implemented in the new line is designed to significantly improve sterility assurance, accuracy of operations, and throughput, thus meeting the highest global regulatory standards.
The $132 million investment showcases the long-term resolve of JHS towards innovation, quality, and supply chain stability while facilitating the easy-to-go injectable program across a vast range of therapeutic areas.
After a fourth line becomes operational, JHS will have increased its total capacity for sterile injectable products in Spokane from the current situation by two times, leaving room for further enhancement of US domestic pharmaceutical manufacturing.
The expansion measures serve to secure the country's health, reduce the use of off-shore supply chains, and contribute to the development of a resilient pharmaceutical ecosystem.
Also Read: Integris Medtech Files DRHP for IPO with SEBI
The CEO of CDMO Sterile Injectables at JHS, Chris Preti, said, "The third line's commissioning is the proof of the organization's commitment to expansion, technological capabilities, and the Spokane community. The fourth line complements us in this effort as we are expanding our workforce, strengthening the US pharmaceutical supply chain, and establishing ourselves as a dependable partner who makes a difference by providing life-saving therapies globally."
